These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33638869)

  • 1. Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol.
    Guo M; Zhao Q; Fan S; Wu Z; Lin L; Chen H; Gao Y; Hai X
    Br J Clin Pharmacol; 2021 Oct; 87(10):4020-4026. PubMed ID: 33638869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
    Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
    Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Speciation analysis of arsenic in urine samples from APL patients treated with single agent As
    Guo M; Li J; Fan S; Liu W; Wang B; Gao C; Zhou J; Hai X
    J Pharm Biomed Anal; 2019 Jul; 171():212-217. PubMed ID: 31009876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
    [No Abstract]   [Full Text] [Related]  

  • 5. Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients.
    Guo M; Lv J; Chen X; Wu M; Zhao Q; Hai X
    Front Oncol; 2022; 12():887026. PubMed ID: 35646703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
    Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells.
    Guo M; Wang W; Hai X; Zhou J
    J Pharm Biomed Anal; 2017 Oct; 145():356-363. PubMed ID: 28711674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
    [No Abstract]   [Full Text] [Related]  

  • 9. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Wang Z; Zhou J; Lu X; Gong Z; Le XC
    Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3.
    Šlejkovec Z; Podgornik H; Černelč P; Falnoga I
    Biometals; 2016 Feb; 29(1):107-18. PubMed ID: 26671504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of arsenic species in leukocytes and granulocytes of acute promyelocytic leukemia patients treated with arsenic trioxide.
    Wang X; Qian Z; Li H; Chen H; Lin L; Guo M; Hai X
    J Pharm Biomed Anal; 2021 Sep; 203():114201. PubMed ID: 34130006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
    Gao C; Hu S; Guo M; Hai X; Zhou J
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment.
    Chen B; Cao F; Lu X; Shen S; Zhou J; Le XC
    Talanta; 2018 Jul; 184():446-451. PubMed ID: 29674067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Chen B; Cao F; Yuan C; Lu X; Shen S; Zhou J; Le XC
    Anal Bioanal Chem; 2013 Feb; 405(6):1903-11. PubMed ID: 23318765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide.
    Zheng Y; Mao YF; Zhao HJ; Chen L; Wang LN; Zhang YX; Hu J; Li JM; Li XY; Zhu HM
    Exp Hematol Oncol; 2021 Feb; 10(1):10. PubMed ID: 33549147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.
    Iriyama N; Yoshino Y; Yuan B; Horikoshi A; Hirabayashi Y; Hatta Y; Toyoda H; Takeuchi J
    J Hematol Oncol; 2012 Jan; 5():1. PubMed ID: 22272800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As
    Liu WS; Wang XY; Lu J; Zhang YM; Ye XM; Li JM; Zhao QL; Wu ZQ; Zhou J; Hai X
    Arch Toxicol; 2020 Apr; 94(4):1203-1213. PubMed ID: 32112223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.
    Au WY; Tam S; Fong BM; Kwong YL
    Blood; 2008 Nov; 112(9):3587-90. PubMed ID: 18703707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.